Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

Stanford University

Status and phase: Enrolling; Phase 3; Phase 2

Conditions: Autism Spectrum Disorder

Treatments: Drug: Placebo; Drug: N acetyl cysteine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05664789

4R00HD101702-03 (U.S. NIH Grant/Contract)

IRB-68353

Details and patient eligibility

About

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.

Enrollment: 144 estimated patients

Sex: All

Ages: 3 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• children between 3 years and 12 years 11 months
• diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview- Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of Symptoms of Autism, or Childhood Autism Rating Scale
• at least moderate severity of restricted and repetitive behaviors defined by a Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥ 11
• physical development indicative of prepubescence as defined by criteria for Tanner Stage 1
• if home address is within 300 miles of the primary study site, participants must pass MR safety screening (e.g., no metal in the body) and attempt baseline neuroimaging (MRI or EEG), otherwise baseline neuroimaging is not required for participation
• have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days) prior to randomization with no anticipated changes during the trial

Exclusion criteria

• presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
• current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
• presence of significant medical problems
• the inability of at least one caregiver to speak and read English to a sufficient level
• participants taking glutathione agents/prodrugs
• history of any adverse effects to glutathione agents/prodrugs
• the inability to drink a sample study compound dissolved in liquid

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

144 participants in 2 patient groups, including a placebo group

N-acetylcysteine

Active Comparator group

Description:

12 week administration of active study compound

Treatment:

Drug: N acetyl cysteine

Placebo

Placebo Comparator group

Description:

12 week administration of matched placebo

Treatment:

Drug: Placebo